导航阿达利穆马布生物类似药:专家意见
Vered Abitbol1, Salim Benkhalifa2, Caroline Habauzit2
1Service de gastroentérologie, Hôpital Cochin, AP-HP, Université Paris Cité, Paris, 75014, France.
Journal of comparative effectiveness research
|October 19, 2023
概括
由于Humira®的专利已经过期,在欧洲和美国已经出现了多种阿达利穆马布生物仿制药. 这篇文章指导临床医生选择最好的阿达利穆马布生物类似剂用于免疫和炎症疾病.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 由于Humira® (adalimumab) 的专利已经过期,导致许多Adalimumab生物类似药在欧洲和美国进入市场.
- 这些生物类似药用于治疗各种免疫和炎症疾病.
研究的目的:
- 探索可用的阿达利穆马布生物类似药的特性.
- 帮助临床医生在各种阿达利穆马布生物类似药选择中进行治疗决策.
- 强调患者与医生的沟通对于生物类似药的处方的重要性.
主要方法:
- 对阿达利穆马布生物类似药的产品特征的审查.
- 疗效,安全性和免疫性数据的比较.
- 对辅助剂,防腐剂和设备类型的差异进行分析.
主要成果:
- 阿达利穆马布生物仿制药的疗效,安全性和免疫性与原始药物具有可比性.
- 生物类似药的主要区别在于辅助剂,防腐剂和装置类型.
- 由于现有的生物类似药的数组,医生决策可能是复杂的.
结论:
- 阿达利穆马布生物仿制药为免疫和炎症性疾病提供了可行的治疗选择.
- 了解生物类似物变异对于有效的临床选择至关重要.
- 与患者的公开沟通对于管理期望和减轻潜在的nocebo效应至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K


